Collision metastasis of prostatic adenocarcinoma and urothelial carcinoma of the bladder

David P. Sellman, Leslie Peard, Greg Simpson, Katrina Lancaster, Sravan Kumar Kavuri, Martha Kennedy Terris, Rabii Hussein Madi

Research output: Contribution to journalArticle

Abstract

The incidence of concomitant prostate adenocarcinoma found in patients with muscle-invasive bladder carcinoma is not uncommon, reaching up to 21%-28%. However, the presence of collision metastasis involving prostate cancer and bladder cancer within the same lymph node is exceedingly rare, with only 5 cases reported to date in the literature. We report a case of collision metastasis of prostate adenocarcinoma and urothelial carcinoma of the bladder in a 73-year-old man who underwent cystoprostatectomy with bilateral pelvic lymph node dissection for high-grade muscle-invasive urothelial carcinoma. Final pathology revealed a pT3aN2 high-grade urothelial carcinoma and pT3N1 Gleason 4 + 4 = 8 adenocarcinoma of the prostate with 12/40 pelvic lymph nodes positive for urothelial carcinoma. One node was positive for both urothelial carcinoma and prostate adenocarcinoma, confirmed by positive staining by p40 and prostate specific antigen(PSA), respectively. Immunohistochemistry is the sole method of confirming collision metastasis of two primary cancers. In this case, we describe immunohistochemical markers for urothelial carcinoma and prostate adenocarcinoma and their clinical implications. One month postoperatively, our patient began adjuvant leuprolide therapy and cycle 1 of gemcitabine and cisplatin chemotherapy, which he is tolerating well.

Original languageEnglish (US)
Pages (from-to)342-344
Number of pages3
JournalUrology Annals
Volume10
Issue number3
DOIs
StatePublished - Jul 1 2018

Fingerprint

Urinary Bladder
Adenocarcinoma
Neoplasm Metastasis
Carcinoma
Prostate
gemcitabine
Urinary Bladder Neoplasms
Lymph Nodes
Leuprolide
Muscles
Prostate-Specific Antigen
Lymph Node Excision
Cisplatin
Prostatic Neoplasms
Immunohistochemistry
Pathology
Staining and Labeling
Drug Therapy
Incidence
Neoplasms

Keywords

  • Bladder cancer
  • collision metastasis
  • immunohistochemistry
  • prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Collision metastasis of prostatic adenocarcinoma and urothelial carcinoma of the bladder. / Sellman, David P.; Peard, Leslie; Simpson, Greg; Lancaster, Katrina; Kavuri, Sravan Kumar; Terris, Martha Kennedy; Madi, Rabii Hussein.

In: Urology Annals, Vol. 10, No. 3, 01.07.2018, p. 342-344.

Research output: Contribution to journalArticle

Sellman, David P. ; Peard, Leslie ; Simpson, Greg ; Lancaster, Katrina ; Kavuri, Sravan Kumar ; Terris, Martha Kennedy ; Madi, Rabii Hussein. / Collision metastasis of prostatic adenocarcinoma and urothelial carcinoma of the bladder. In: Urology Annals. 2018 ; Vol. 10, No. 3. pp. 342-344.
@article{b16cdc9370c74e70916ce75f9cfcf20e,
title = "Collision metastasis of prostatic adenocarcinoma and urothelial carcinoma of the bladder",
abstract = "The incidence of concomitant prostate adenocarcinoma found in patients with muscle-invasive bladder carcinoma is not uncommon, reaching up to 21{\%}-28{\%}. However, the presence of collision metastasis involving prostate cancer and bladder cancer within the same lymph node is exceedingly rare, with only 5 cases reported to date in the literature. We report a case of collision metastasis of prostate adenocarcinoma and urothelial carcinoma of the bladder in a 73-year-old man who underwent cystoprostatectomy with bilateral pelvic lymph node dissection for high-grade muscle-invasive urothelial carcinoma. Final pathology revealed a pT3aN2 high-grade urothelial carcinoma and pT3N1 Gleason 4 + 4 = 8 adenocarcinoma of the prostate with 12/40 pelvic lymph nodes positive for urothelial carcinoma. One node was positive for both urothelial carcinoma and prostate adenocarcinoma, confirmed by positive staining by p40 and prostate specific antigen(PSA), respectively. Immunohistochemistry is the sole method of confirming collision metastasis of two primary cancers. In this case, we describe immunohistochemical markers for urothelial carcinoma and prostate adenocarcinoma and their clinical implications. One month postoperatively, our patient began adjuvant leuprolide therapy and cycle 1 of gemcitabine and cisplatin chemotherapy, which he is tolerating well.",
keywords = "Bladder cancer, collision metastasis, immunohistochemistry, prostate cancer",
author = "Sellman, {David P.} and Leslie Peard and Greg Simpson and Katrina Lancaster and Kavuri, {Sravan Kumar} and Terris, {Martha Kennedy} and Madi, {Rabii Hussein}",
year = "2018",
month = "7",
day = "1",
doi = "10.4103/UA.UA_97_17",
language = "English (US)",
volume = "10",
pages = "342--344",
journal = "Urology Annals",
issn = "0974-7796",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "3",

}

TY - JOUR

T1 - Collision metastasis of prostatic adenocarcinoma and urothelial carcinoma of the bladder

AU - Sellman, David P.

AU - Peard, Leslie

AU - Simpson, Greg

AU - Lancaster, Katrina

AU - Kavuri, Sravan Kumar

AU - Terris, Martha Kennedy

AU - Madi, Rabii Hussein

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The incidence of concomitant prostate adenocarcinoma found in patients with muscle-invasive bladder carcinoma is not uncommon, reaching up to 21%-28%. However, the presence of collision metastasis involving prostate cancer and bladder cancer within the same lymph node is exceedingly rare, with only 5 cases reported to date in the literature. We report a case of collision metastasis of prostate adenocarcinoma and urothelial carcinoma of the bladder in a 73-year-old man who underwent cystoprostatectomy with bilateral pelvic lymph node dissection for high-grade muscle-invasive urothelial carcinoma. Final pathology revealed a pT3aN2 high-grade urothelial carcinoma and pT3N1 Gleason 4 + 4 = 8 adenocarcinoma of the prostate with 12/40 pelvic lymph nodes positive for urothelial carcinoma. One node was positive for both urothelial carcinoma and prostate adenocarcinoma, confirmed by positive staining by p40 and prostate specific antigen(PSA), respectively. Immunohistochemistry is the sole method of confirming collision metastasis of two primary cancers. In this case, we describe immunohistochemical markers for urothelial carcinoma and prostate adenocarcinoma and their clinical implications. One month postoperatively, our patient began adjuvant leuprolide therapy and cycle 1 of gemcitabine and cisplatin chemotherapy, which he is tolerating well.

AB - The incidence of concomitant prostate adenocarcinoma found in patients with muscle-invasive bladder carcinoma is not uncommon, reaching up to 21%-28%. However, the presence of collision metastasis involving prostate cancer and bladder cancer within the same lymph node is exceedingly rare, with only 5 cases reported to date in the literature. We report a case of collision metastasis of prostate adenocarcinoma and urothelial carcinoma of the bladder in a 73-year-old man who underwent cystoprostatectomy with bilateral pelvic lymph node dissection for high-grade muscle-invasive urothelial carcinoma. Final pathology revealed a pT3aN2 high-grade urothelial carcinoma and pT3N1 Gleason 4 + 4 = 8 adenocarcinoma of the prostate with 12/40 pelvic lymph nodes positive for urothelial carcinoma. One node was positive for both urothelial carcinoma and prostate adenocarcinoma, confirmed by positive staining by p40 and prostate specific antigen(PSA), respectively. Immunohistochemistry is the sole method of confirming collision metastasis of two primary cancers. In this case, we describe immunohistochemical markers for urothelial carcinoma and prostate adenocarcinoma and their clinical implications. One month postoperatively, our patient began adjuvant leuprolide therapy and cycle 1 of gemcitabine and cisplatin chemotherapy, which he is tolerating well.

KW - Bladder cancer

KW - collision metastasis

KW - immunohistochemistry

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85050309689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050309689&partnerID=8YFLogxK

U2 - 10.4103/UA.UA_97_17

DO - 10.4103/UA.UA_97_17

M3 - Article

AN - SCOPUS:85050309689

VL - 10

SP - 342

EP - 344

JO - Urology Annals

JF - Urology Annals

SN - 0974-7796

IS - 3

ER -